- Previous Close
7,089.00 - Open
7,067.30 - Bid --
- Ask --
- Day's Range
6,840.00 - 7,067.30 - 52 Week Range
4,785.00 - 8,139.00 - Volume
20,925 - Avg. Volume
35,206 - Market Cap (intraday)
172.812B - Beta (5Y Monthly) 0.29
- PE Ratio (TTM)
212.80 - EPS (TTM)
32.46 - Earnings Date Feb 6, 2025 - Feb 10, 2025
- Forward Dividend & Yield 24.00 (0.32%)
- Ex-Dividend Date Jul 5, 2024
- 1y Target Est
--
AstraZeneca Pharma India Limited, a biopharmaceutical company, engages in manufacturing, distributing, and marketing of pharmaceutical products in India and internationally. It manufactures and sells cardiovascular disease, renal, and metabolism medicines under the CRESTOR, Forxiga, BRILINTA, Xigduo, and Seloken XL brand names; oncology medicines under the TAGRISSO, CALQUENCE, Lynparza, ENHERTU, IMFINZI, and Zoladex brand names; rare diseases medicines under the Koselugo brand name; and respiratory medicines under the Symbicort and Fasenra brand names. The company also offers medicines for diabetes and immunology diseases. It also provides clinical trial services. The company was incorporated in 1979 and is based in Bengaluru, India. AstraZeneca Pharma India Limited is a subsidiary of AstraZeneca Pharmaceuticals AB.
www.astrazeneca.in940
Full Time Employees
March 31
Fiscal Year Ends
Sector
Recent News: ASTRAZEN.NS
View MorePerformance Overview: ASTRAZEN.NS
Trailing total returns as of 1/10/2025, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ASTRAZEN.NS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ASTRAZEN.NS
View MoreValuation Measures
Market Cap
172.81B
Enterprise Value
167.90B
Trailing P/E
210.78
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
11.63
Price/Book (mrq)
25.42
Enterprise Value/Revenue
11.31
Enterprise Value/EBITDA
126.88
Financial Highlights
Profitability and Income Statement
Profit Margin
6.91%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
13.88B
Net Income Avi to Common (ttm)
958.6M
Diluted EPS (ttm)
32.46
Balance Sheet and Cash Flow
Total Cash (mrq)
5.06B
Total Debt/Equity (mrq)
0.64%
Levered Free Cash Flow (ttm)
--